Paragon Bioservices, a biopharmaceuticals and vaccines manufacturer, recently gained a contract from the International AIDS Vaccine Initiative (IAVI) to create an HIV vaccine candidate.
Scientists have found that if an experimental vaccine candidate can provoke the immune system into creating its own antibodies, HIV infections can be stopped. This was confirmed in a study that involved mice this year. The antibodies matured to the extent that they blocked the infection within the laboratory mice.
“We are honored to be a part of scientific efforts to prevent HIV, especially considering the enormous progress in the understanding of HIV transmission, immunology and vaccinology in the past few years that is bringing us closer to an effective AIDS vaccine,”
Paragon Founder and CEO
Marco Chacon said. “Paragon has helped develop and manufacture over 50 different biotherapeutics and vaccines. Our quality, process development and GMP manufacturing teams have considerable experience in the development and manufacturing of vaccine candidates — including recent contracts with the U.S. government and ongoing contracts with biotechnology and major pharmaceutical clients.”
This contract requires the company to process, analyze and manufacture the potential vaccine. The candidate will need to pass animal and clinical testing.
